Literature DB >> 12714807

Comparison of the bactericidal activity of moxifloxacin and levofloxacin against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniae.

S W Lemmen1, H Häfner, S Klik, R Lütticken, D Zolldann.   

Abstract

In addition to MIC and MBC tests in this study the serum bactericidal activity of 3.1 microg/ml of moxifloxacin or 5.2 microg/ml of levofloxacin was determined against ten susceptible strains of S. aureus, S. epidermidis, E. coli and K. pneumoniae. Moxifloxacin achieved markedly better activity against S. aureus and S. epidermidis as compared to levofloxacin. Activity of moxifloxacin against E. coli and K. pneumoniae was excellent but not superior to levofloxacin. In conclusion both fluorquinolones are highly effective against E. coli and K. pneumoniae, moxifloxacin being superior with respect to gram-positives like S. aureus and S. epidermidis. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12714807     DOI: 10.1159/000069779

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  9 in total

1.  Exploring the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials against Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  Brian J Werth
Journal:  J Antimicrob Chemother       Date:  2017-05-01       Impact factor: 5.790

2.  3D bioprinted scaffolds for diabetic wound-healing applications.

Authors:  Katie Glover; Essyrose Mathew; Giulia Pitzanti; Erin Magee; Dimitrios A Lamprou
Journal:  Drug Deliv Transl Res       Date:  2022-01-11       Impact factor: 4.617

3.  A focus on intra-abdominal infections.

Authors:  Massimo Sartelli
Journal:  World J Emerg Surg       Date:  2010-03-19       Impact factor: 5.469

4.  Italian guidelines for the diagnosis and infectious disease management of osteomyelitis and prosthetic joint infections in adults.

Authors:  S Esposito; S Leone; M Bassetti; S Borrè; F Leoncini; E Meani; M Venditti; F Mazzotta
Journal:  Infection       Date:  2009-11-10       Impact factor: 7.455

5.  No Outbreak of Vancomycin and Linezolid Resistance in Staphylococcal Pneumonia over a 10-Year Period.

Authors:  Josef Yayan; Beniam Ghebremedhin; Kurt Rasche
Journal:  PLoS One       Date:  2015-09-23       Impact factor: 3.240

6.  Emergency 1-stage anterior approach for cervical spine infection complicated by epidural abscess.

Authors:  Haoxi Li; Zhaoxiong Chen; Zhiyao Yong; Xinhua Li; Yufeng Huang; Desheng Wu
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

7.  Rifampicin enhances activity of daptomycin and vancomycin against both a polysaccharide intercellular adhesin (PIA)-dependent and -independent Staphylococcus epidermidis biofilm.

Authors:  Michael E Olson; Shawn R Slater; Mark E Rupp; Paul D Fey
Journal:  J Antimicrob Chemother       Date:  2010-08-18       Impact factor: 5.790

8.  Moxifloxacin in the treatment of skin and skin structure infections.

Authors:  David Rp Guay
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

9.  Optimized Preparation of Levofloxacin Loaded Polymeric Nanoparticles.

Authors:  Manuel López-López; Angela Fernández-Delgado; María Luisa Moyá; Daniel Blanco-Arévalo; Cecilio Carrera; Rafael R de la Haba; Antonio Ventosa; Eva Bernal; Pilar López-Cornejo
Journal:  Pharmaceutics       Date:  2019-01-30       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.